Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has launched the 'Get Uncomfortable' campaign featuring Toni Braxton, aimed at raising awareness about lupus nephritis and the importance of kidney health. The initiative encourages individuals with lupus nephritis to undergo routine testing and regular doctor visits to prevent irreversible kidney damage. Braxton, diagnosed with lupus in 2008, shares her personal experience to inspire others to advocate for their health. Since its inception in October 2022, the campaign has reached numerous patients, providing critical information regarding kidney health. Notably, lupus nephritis disproportionately affects women of color, emphasizing the need for increased awareness and action.

Shareholder MKT Capital Ltd., owning 4.2% of Aurinia Pharmaceuticals (AUPH), has publicly criticized the company’s management for their poor performance and excessive executive compensation, including a total of $26 million to CEO Peter Greenleaf from 2019 to 2022. MKT Capital urges a strategic review process and suggests a potential sale of the company, estimating it could yield $28 per share, representing a 192% premium for shareholders. Concerns were raised over the board's misalignment with shareholder interests, inadequate growth of LUPKYNIS—only treating 1,500 patients and failing to diversify the drug pipeline. MKT plans to withhold support for the election of key directors at the upcoming Annual General Meeting on May 17, 2023.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its financial and operational results for Q1 2023 on May 4, 2023, before market opening. The management team will hold a conference call/webcast at 8:30 am ET to discuss these results and update the business. Interested participants can join by dialing (888) 645-4404 / (862) 298-0702, with a replay available on the company’s website thereafter.

Aurinia focuses on developing therapies for autoimmune, kidney, and rare diseases, with its flagship product being LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for active lupus nephritis introduced in January 2021. The company's headquarters are located in Edmonton, Alberta, with a U.S. commercial hub in Rockville, Maryland.

Aurinia Pharmaceuticals announces the issuance of U.S. Patent No. 11,622,991 for its product LUPKYNIS, which provides a refined method for treating Lupus Nephritis. This patent outlines a proprietary dosing regimen that combines LUPKYNIS with mycophenolate mofetil and corticosteroids, utilizing eGFR to optimize dosing. The new patent enhances intellectual property protection for LUPKYNIS until 2037 and follows a prior allowance from the USPTO. LUPKYNIS is the first FDA-approved oral treatment for active lupus nephritis, affecting approximately 200,000-300,000 individuals in the U.S. with systemic lupus erythematosus (SLE).

Aurinia Pharmaceuticals (AUPH) announced encouraging results from its AURORA Renal Biopsy Sub-Study on LUPKYNIS, a treatment for active lupus nephritis (LN). The study demonstrated that patients receiving LUPKYNIS, alongside standard care (mycophenolate mofetil and low-dose steroids), experienced significant reductions in proteinuria while maintaining stable renal function, evidenced by stable eGFR slopes. Histologic improvements were observed, with chronicity scores stable over the 18-month period. Dr. Greg Keenan emphasized the differentiation of LUPKYNIS from first-generation calcineurin inhibitors, supporting its long-term efficacy and safety.